CoChat

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib

Open access
Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., Hochhaus, A. · 2008 · Haematologica
Cited by 38

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Dasatinib is a multitargeted inhibitor of ABL, the SRC family, and other tyrosine kinases. We sought to evaluate the effects of this drug on cell proliferation, centrosomes, mitotic spindles, and cell cycle progression in vitro and in vivo. DESIGN AND METHODS: Human dermal fibroblasts, Chinese hamster cells, human osteosarcoma cells, and blood and bone marrow mononuclear cells from 32 patients with chronic myeloid leukemia, gastrointestinal stromal tumor, and systemic mastocytosis as well as from six healthy individuals were investigated. The effects of dasatinib were compared with those of the ABL inhibitors imatinib and nilotinib, the SRC inhibitor PP2, and the ABL/LYN inhibitor INNO-406. RESULTS: Dasatinib induced G(1) phase arrest in all cell lines and this was associated with a decline in cyclin D1 levels. In vitro, centrosomal aberrations, a decrease of mitotic spindles, and G(1) phase arrest were observed. In patients, centrosome alterations were found in a median of 17% (range, 10-22%) of cells with a decrease of spindles in 8/18 patients. In comparison, imatinib, nilotinib and PP2 led to centrosome aberrations without G(1) phase arrest. INNO-406 was associated with centrosome aberrations and cell cycle arrest in G(1) phase. CONCLUSIONS: Dasatinib blocks the G(1)/S transition and inhibits cell growth. It induces centrosomal aberrations and a decrease of mitotic spindles. The effects suggest an involvement of SRC and ABL inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.12793

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

    Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 1×

    “Patients on dasatinib therapy (CML, n=17; GIST, n=1) 18 Age at start of dasatinib, years 57 (26-75) % male 50 Previous therapy 18 (100) Imatinib 4 (22) Imatinib, HU 1 (6) Imatinib, IFN 4 (22) Imatinib, HU, IFN 6 (33) Imatinib, HU, IFN, AraC 2 (11) Follow-up of all patients after diagnosis, months 75 (10-198) Follow-up…”
    Background
  • A renaissance for SRC

    Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113 · cited 1×

    “Patients on dasatinib therapy (CML, n=17; GIST, n=1) 18 Age at start of dasatinib, years 57 (26-75) % male 50 Previous therapy 18 (100) Imatinib 4 (22) Imatinib, HU 1 (6) Imatinib, IFN 4 (22) Imatinib, HU, IFN 6 (33) Imatinib, HU, IFN, AraC 2 (11) Follow-up of all patients after diagnosis, months 75 (10-198) Follow-up…”
    Background

Show all 2 references

Cited by

See all 38

Metadata

Authors
Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., & Hochhaus, A.
Venue
Haematologica
Published
2008-08-01
Volume
93
Issue
8
Pages
1145-1154
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2118978570
Cited by
38
References
2
FWCI
1.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. https://app.cochat.ai/papers/10.3324/haematol.12793
The paper
Fabarius, A., Giehl, M., Rebacz, B., Kramer, A., Frank, O., Haferlach, C., Duesberg, P., Hehlmann, R., Seifarth, W., & Hochhaus, A. (2008). Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica. https://doi.org/10.3324/haematol.12793

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.